Advertisement
Advertisement

OSTX

OSTX logo

OS Therapies Incorporated

1.60
USD
Sponsored
-0.03
-1.84%
Aug 07, 15:59 UTC -4
Closed
exchange

Pre-Market

1.60

0.00
+0.31%

OSTX Earnings Reports

Positive Surprise Ratio

OSTX beat 0 of 7 last estimates.

0%

Next Report

In 3 Days
Date of Next Report
Aug 13, 2026
Estimate for Q2 26 (Revenue/ EPS)
--
/
-$0.21
Implied change from Q1 26 (Revenue/ EPS)
--
/
-22.22%
Implied change from Q2 25 (Revenue/ EPS)
--
/
+10.53%

OS Therapies Incorporated earnings per share and revenue

On May 18, 2026, OSTX reported earnings of -0.27 USD per share (EPS) for Q1 26, missing the estimate of -0.18 USD, resulting in a -49.83% surprise. Revenue reached --, compared to an expected 330.14 thousand, with a -100.00% difference. The market reacted with a -7.98% price change (close before vs. close after earnings).
Looking ahead to Q2 26, -- analysts forecast an EPS of -0.21 USD, with revenue projected to reach -- USD, implying an decrease of -22.22% EPS, and increase of 0.00% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
ANI Pharmaceuticals, Inc.
Report Date
Aug 07, 2026 For Q2 26
Estimate
$2.09
Actual
$2.21
Surprise
+5.69%
logo
Zymeworks Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.46
Actual
-$0.62
Surprise
-32.31%
logo
Ocugen, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.05
Actual
-$0.07
Surprise
-26.35%
logo
Entera Bio Ltd. Ordinary Shares
Report Date
Aug 07, 2026 For Q2 26
Estimate
-$0.08
Actual
-$0.14
Surprise
-71.57%
logo
Axsome Therapeutics, Inc
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.86
Actual
-$0.99
Surprise
-14.90%
logo
Cytokinetics Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$1.67
Actual
-$1.50
Surprise
+10.35%
logo
Apogee Therapeutics, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$1.09
Actual
-$1.13
Surprise
-4.39%
logo
Edgewise Therapeutics, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.47
Actual
-$0.53
Surprise
-10.55%
logo
Denali Therapeutics Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.66
Actual
-$0.68
Surprise
-1.51%
logo
Celldex Therapeutics, Inc
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$1.07
Actual
-$0.94
Surprise
+12.79%
FAQ
For Q1 2026, OS Therapies Incorporated reported EPS of -$0.27, missing estimates by -49.83%, and revenue of $0.00, -100% below expectations.
The stock price moved down -7.98%, changed from $1.88 before the earnings release to $1.73 the day after.
The next earning report is scheduled for Aug 13, 2026.
Based on -- analysts, OS Therapies Incorporated is expected to report EPS of -$0.21 and revenue of -- for Q2 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement